Drug Trial Radar · NCT01906658
A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis
Last checked: Nov 20, 2026Latest source record: Jan 6, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
43
Actual
Start
Jul 2013
Primary completion
Nov 2014
Study completion Dec 2014
Sponsor
- Lead sponsor
- MallinckrodtIndustry
- Sponsor type
- Industry
- First posted
- Jul 24, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This 8-week randomized, open-label evaluation will examine the acute safety and tolerability of 4 different dosing regimens of Acthar to inform dose selection for future studies of Acthar in patients with Amyotrophic Lateral Sclerosis (ALS). The study will also investigate the mean rate of change in the ALSFRS-R total score as an exploratory endpoint to help design future studies. This study will enroll up to 40 patients and include an optional 28-week open-label extension period plus a 3-week treatment taper and 1-week follow up period. After completion of Week 8, patients enrolled in a treatment group that is considered safe and tolerable at that time have the option to continue into the open-label extension period. A 3-week treatment taper and a follow-up visit are planned for all patients enrolled in the study, beginning either at Week 8 or at Week 36 if a patient continues into the optional open-label extension period.
Conditions
- Amyotrophic Lateral Sclerosis
Interventions
Repository corticotropin injectionDrug
Acthar given SC twice weekly (80 U or 56 U) or daily (24 U or 16 U) for 8 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Subjects With Adverse Events (AEs) That Required Study Drug Discontinuation or Could Not be Controlled With Concomitant MedicationTime frame: Baseline to Week 8
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
Questcor Investigational Site
Birmingham, Alabama
Questcor Investigational Site
Phoenix, Arizona
Questcor Investigational Site
San Francisco, California
Questcor Investigational Site
Stanford, California
Questcor Investigational Site
Jacksonville, Florida
Questcor Investigational Site
Miami, Florida
Questcor Investigational Site
Tampa, Florida
Questcor Investigational Site
Atlanta, Georgia
Questcor Investigational Site
Kansas City, Kansas
Questcor Investigational Site
Rochester, Minnesota
Questcor Investigational Site
Lincoln, Nebraska
Questcor Investigational Site
Hershey, Pennsylvania
Questcor Investigational Site
Pittsburgh, Pennsylvania
Questcor Investigational Site
Memphis, Tennessee
Questcor Investigational Site
Dallas, Texas
Questcor Investigational Site
Houston, Texas
Questcor Investigational Site
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.